MEDFORD, Mass., Feb. 19, 2018 /PRNewswire/ -- Seventh Sense
Biosystems (7SBio) today announced a paper published in Nature
Biomedical Engineering that compares the performance of the
company's TAPĀ® device to traditional venipuncture. TAP is a
virtually painless, one-step blood collection device that uses
microneedles to collect blood quickly and conveniently. TAP
received U.S. Food and Drug Administration (FDA) 510(k) premarket
clearance in 2017.
"TAP will make it possible to draw blood in many different
settings. In the future, we envision people being able to quickly,
safely and painlessly draw their own blood at home or at work and
send a sample to be tested," Harry W Wilcox, CEO of 7SBio.
The new Nature Biomedical Engineering paper
details the development of TAP and reports the results of a
clinical study evaluating TAP for HbA1c determinations. Conducted
at three hospital sites with over 140 patients, the study collected
blood using TAP and venipuncture and then compared the results
using two testing technologies, the DCA Vantage (Siemens) and the
Afinion AS100 (Alere).
The authors found that samples collected from TAP were equally
suitable for performing HbA1c determinations as samples collected
via venipuncture. Importantly, the paper's authors also report that
patients found blood collection with TAP significantly less painful
than venipuncture.
"Everyone has become deeply accustomed to on-demand technology.
As medical devices and other smart technology further integrate
with daily health and fitness routines, we will continue to see
healthcare become more convenient," said Bob Langer, Ph.D., 7SBio co-founder and one of
13 Institute Professors at the Massachusetts Institute of
Technology (MIT's highest
honor). "Technologies like TAP represent the future of how patients
will interact with the healthcare system."
To read the full Nature Biomedical Engineering paper,
please visit http://nature.com/articles/doi:10.1038/s41551-018-0194-1
About Seventh Sense
Seventh Sense Biosystems has designed and developed TAP, the
world's first push-button blood collection device. It makes the
process simple, convenient, and painless. $50 billion is
spent annually on diagnostics and consumers are demanding more from
the healthcare system. The company aims to create a new standard
for blood collection that increases patient compliance with testing
orders, leading to faster diagnoses and better outcomes. Future
versions of TAP will be designed to enable patients to collect
their own blood anywhere. 7SBio is funded by Flagship Pioneering
and Polaris Partners, as well as Novartis ($NVS), Siemens
($SIEGn.DE), and LabCorp ($LH). The Company was founded by Flagship
VentureLabs along with academics from MIT, executives from the
pharmaceutical and diagnostic industries, and a former general
counsel from the FDA. For more information: www.7sbio.com.
Media Contact
Kristina Beacom
+1 (617) 547 7246
PR@7sbio.com
View original
content:http://www.prnewswire.com/news-releases/seventh-senses-next-generation-blood-collection-device-featured-in-nature-biomedical-engineering-300600487.html
SOURCE Seventh Sense Biosystems